ADMS - The Buzz Show: Adamas Pharmaceuticals (NASDAQ: ADMS) to be Acquired by Supernus Pharma

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adamas Pharmaceuticals, Inc. Announces Definitive Agreement to be Acquired by Supernus Pharmaceuticals, Inc”

Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) surged over 72% in premarket trading after the company announced a definitive agreement to be acquired by Supernus Pharmaceuticals, Inc.

The transaction has a total consideration of up to $9.10 per share and will strengthen Supernus Pharmaceuticals’ CNS product portfolio with the acquisition of two marketed products, GOCOVRI and Osmolex ER.

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

For more information, please visit: Adamas Pharmaceuticals, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Adamas Pharmaceuticals (NASDAQ: ADMS) to be Acquired by Supernus Pharma first appeared on Financial Buzz .

For further details see: